Abstract. The 17th Annual Frontiers in Cancer Science (FCS) conference (2025) highlighted the convergence of multiomics, computational biology, and ancestry-specific genomics to advance proactive ...
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license ...
ACR246 is a novel anti-5T4 antibody-drug conjugate (ADC) composed of a fully human monoclonal antibody, a proprietary topoisomerase I inhibitor payload, and an innovative stable cleavable linker, with ...
MATISSE (NCT05742607) is a single arm phase 2 study, investigating perioperative IPH5201+durva, in addition to neoadjuvant CT in previously untreated pts with resectable stage II to IIIA NSCLC. The ...
Brian M. Wolpin, Benjamin L. Musher, Gulam A. Manji, Wungki Park, Alexander Spira, Nilofer Azad, Vaia Florou, Tiago Biachi De Castria, Mark H. O'Hara, Erkut Borazanci, Aparna Parikh, John Strickler, ...
You do not currently have access to this content.
AbstractIntroduction:. Although most PD-L1-positive patients with metastatic triple-negative breast cancer (mTNBC) respond to immune check point inhibitors (ICIs) many either do not respond or develop ...
In DESTINY-Breast03 (NCT03529110), T-DXd showed statistically significant and clinically meaningful improvement in progression-free survival (PFS) and overall survival (OS) vs T-DM1 in pts with HER2+ ...
AbstractBackground:. JS107 is a monomethyl auristatin E conjugated, CLDN18.2 specific ADC. JS107 exhibited potent anti-tumor activities in preclinical studies with a tolerable safety profile. Here we ...
Abstract. The 5-year survival rate for stage 4 advanced cancer is 5.8% for stomach cancer, 17% for colon cancer, 8.4% for lung cancer (NSCLC), 4.4% for liver cancer and 38.6% for breast cancer, 5.1% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results